anti-IL-13Ra2 CAR T-cell therapy (Carsgen Therapeutics)

N/A

Report date: 2025/01/15 13:53:46

Base Information

Drug Nameanti-IL-13Ra2 CAR T-cell therapy (Carsgen Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulators

TargetsInterleukin-13 receptor subunit alpha-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesCarsgen Therapeutics ltd

China Registration ClassN/A

Develop Information

Active CompaniesCarsgen Therapeutics ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A